RCKT - Latest News
Rocket Pharmaceuticals, Inc. (RCKT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $242.6M. Beta to the broader market is 0.50.
The article list below shows the most recent RCKT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RCKT Headlines
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
proactiveinvestors.com - Oct 7, 2026
Rocket Pharmaceuticals (NASDAQ: RCKT) shares rose 4% on Wednesday after the biotechnology company secured access to up to $150 million under a credit
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
businesswire.com - Oct 7, 2026
CRANBURY, N. J.
Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan Capital
defenseworld.net - Oct 7, 2026
Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report)'s stock had its "buy" rating reissued by Chardan Capital in a report issued on Wednesday, Benz
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
defenseworld.net - Oct 7, 2026
Rocket Pharmaceuticals (NASDAQ: RCKT) outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
seekingalpha.com - Oct 7, 2026
Rocket Pharmaceuticals, Inc.
How News Affects RCKT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RCKT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RCKT news questions
- What is the latest RCKT news headline?
- The most recent RCKT headline (Oct 7, 2026) is "Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RCKT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RCKT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RCKT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.